Valneva Se ADR (VALN)

Jan 6, 2025, 11:45 AM EST - 11 days ago

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Dec 19, 2024, 2:00 AM EST - 4 weeks ago

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

Dec 4, 2024, 1:00 AM EST - 6 weeks ago

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Dec 3, 2024, 1:00 AM EST - 6 weeks ago

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Nov 26, 2024, 11:45 AM EST - 7 weeks ago

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

Nov 15, 2024, 11:21 AM EST - 2 months ago

European And US Vaccine Stocks Are Under Pressure - Here's WHy

AZN BNTX GSK INO MRK SNY

Nov 13, 2024, 11:45 AM EST - 2 months ago

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Nov 9, 2024, 1:10 PM EST - 2 months ago

Valneva SE (VALN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 1:00 AM EST - 2 months ago

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

Oct 21, 2024, 11:45 AM EDT - 3 months ago

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

Oct 16, 2024, 11:45 AM EDT - 3 months ago

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Oct 10, 2024, 1:00 AM EDT - 3 months ago

Valneva Hosts Investor Day in New York City

Oct 3, 2024, 1:00 AM EDT - 3 months ago

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET

Sep 18, 2024, 1:00 AM EDT - 4 months ago

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada

Sep 13, 2024, 2:30 AM EDT - 4 months ago

Valneva Announces the Success of its Private Placement Raising approximately €60 Million

Sep 12, 2024, 4:05 PM EDT - 4 months ago

Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros

Sep 3, 2024, 6:50 AM EDT - 4 months ago

Pfizer and Valneva report positive results in mid-stage trial of Lyme disease vaccine

PFE

Sep 3, 2024, 1:00 AM EDT - 4 months ago

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

PFE

Aug 13, 2024, 1:00 AM EDT - 5 months ago

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

Aug 1, 2024, 1:00 AM EDT - 6 months ago

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World's Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

Jul 22, 2024, 1:00 AM EDT - 6 months ago

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World's First Chikungunya Vaccine

Jul 18, 2024, 2:05 PM EDT - 6 months ago

Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026

PFE

Jul 17, 2024, 4:00 PM EDT - 6 months ago

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

PFE

Jul 1, 2024, 1:00 AM EDT - 7 months ago

Valneva Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, IXCHIQ®

Jun 26, 2024, 11:45 AM EDT - 7 months ago

Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

Jun 24, 2024, 1:00 AM EDT - 7 months ago

Valneva Announces Health Canada Approval of the World's First Chikungunya Vaccine, IXCHIQ®

Jun 5, 2024, 1:00 AM EDT - 8 months ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Jun 4, 2024, 11:35 AM EDT - 8 months ago

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

Jun 3, 2024, 11:35 AM EDT - 8 months ago

Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases

May 31, 2024, 11:35 AM EDT - 8 months ago

Valneva Receives EMA's Positive CHMP Opinion for its Chikungunya Vaccine

May 31, 2024, 6:48 AM EDT - 8 months ago

EU regulator recommends use of Valneva's chikungunya vaccine

May 21, 2024, 1:00 AM EDT - 8 months ago

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

May 13, 2024, 1:00 AM EDT - 8 months ago

Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine

May 7, 2024, 1:00 AM EDT - 9 months ago

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Mar 26, 2024, 2:00 AM EDT - 10 months ago

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Mar 25, 2024, 2:00 AM EDT - 10 months ago

Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

Mar 21, 2024, 2:00 AM EDT - 10 months ago

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

Mar 20, 2024, 4:22 PM EDT - 10 months ago

Valneva SE (VALN) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 2:48 AM EDT - 10 months ago

French biotech company Valneva raises product sales guidance

Mar 20, 2024, 2:00 AM EDT - 10 months ago

Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

Mar 18, 2024, 2:00 AM EDT - 10 months ago

Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

Mar 4, 2024, 1:00 AM EST - 11 months ago

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Feb 29, 2024, 1:00 AM EST - 11 months ago

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ®

Feb 15, 2024, 1:00 AM EST - 1 year ago

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

Feb 5, 2024, 1:20 AM EST - 1 year ago

Valneva sells chikungunya vaccine priority review voucher for $103 mln

Feb 5, 2024, 1:00 AM EST - 1 year ago

Valneva Announces Sale of Priority Review Voucher for $103 Million

Jan 10, 2024, 1:00 AM EST - 1 year ago

Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine

Jan 4, 2024, 11:45 AM EST - 1 year ago

Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum

Dec 29, 2023, 4:30 PM EST - 1 year ago

Valneva Provides Updated 2023 Financial Guidance

Dec 20, 2023, 11:45 AM EST - 1 year ago

Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors